Type I Hypersensitivity Completed Phase 3 Trials for Abrocitinib (DB14973)

Back to Type I Hypersensitivity

Also known as: Immediate Hypersensitivity / Hypersensitivity, Immediate / Immediate Type Hypersensitivity / Immediate hypersensitivity reaction / Immediate hypersensitivity reactions / Allergen-mediated IgE Allergy / Immediate hypersensitivity (disorder) / Hypersensitivity type I / Hypersensitivity type I NOS / Immunoglobulin E-mediated allergic disorder (disorder)

Indication	Status	Phase
DBCOND0030618 (Type I Hypersensitivity)	Completed	3

clinicaltrials.gov Identifier	Title	Purpose	Drugs
NCT03720470	Study Evaluating Efficacy and Safety of PF-04965842 and Dupilumab in Adult Subjects With Moderate to Severe Atopic Dermatitis on Background Topical Therapy	Treatment	Abrocitinib (DB14973) Dupilumab (DB12159)
NCT03627767	Study to Investigate Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years and Over With Moderate to Severe Atopic Dermatitis With the Option of Rescue Treatment in Flaring Subjects	Treatment	Abrocitinib (DB14973)